The effects of erythropoietin signaling on telomerase regulation in non-erythroid malignant and non-malignant cells

被引:1
|
作者
Uziel, Orit [1 ]
Kanfer, Gil [1 ,2 ]
Beery, Einat [1 ]
Yelin, Dana [3 ]
Shepshelovich, Daniel [3 ]
Bakhanashvili, Mary [4 ]
Nordenberg, Jardena [1 ,2 ,5 ]
Lahav, Meir [1 ,3 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Felsenstein Med Res Ctr, Ramat Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Ramat Aviv, Israel
[3] Tel Aviv Univ, Sackler Sch Med, Ramat Aviv, Israel
[4] Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel
[5] Beilinson Med Ctr, Endocrinol Lab, IL-49100 Petah Tiqwa, Israel
关键词
Erythropoietin; Telomerase; Telomeres; Lyn-src; RECEPTOR; GROWTH;
D O I
10.1016/j.bbrc.2014.05.105
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Treatment with erythropoietin (EPO) in several cancers is associated with decreased survival due to cancer progression. Due to the major importance of telomerase in cancer biology we hypothesized that some of these effects may be mediated through EPO effect on telomerase. For this aim we explored the possible effects of EPO on telomerase regulation, cell migration and chemosensitivity in non-erythroid malignant and non-malignant cells. Cell proliferation, telomerase activity (TA) and cell migration increased in response to EPO. EPO had no effect on cancer cells sensitivity to cisplatinum and on the cell cycle status. The inhibition of telomerase modestly repressed the proliferative effect of EPO. Telomere shortening caused by long term inhibition of the enzyme abolished the effect of EPO, suggesting that EPO effects on cancer cells are related to telomere dynamics. TA was correlated with the levels of Epo-R. The increase in TA was mediated post-translationally through the Lyn-Src and not the canonical JAK2 pathway. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:274 / 282
页数:9
相关论文
共 50 条
  • [21] NON-MALIGNANT TUMORS
    COX, JD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1981, 7 (08): : 1129 - 1130
  • [22] EXPRESSION AND ASSEMBLY OF SPECTRIN IN ERYTHROID AND NON-ERYTHROID CELLS
    LAZARIDES, E
    MOON, RT
    NELSON, WJ
    JOURNAL OF CELL BIOLOGY, 1984, 99 (04): : A347 - A347
  • [23] Transcriptional regulation of the KEL gene and Kell protein expression in erythroid and non-erythroid cells
    Camara-Clayette, V
    Rahuel, C
    Lopez, C
    Hattab, C
    Verkarre, V
    Bertrand, O
    Cartron, JP
    BIOCHEMICAL JOURNAL, 2001, 356 : 171 - 180
  • [24] ROLE OF CYTOFLUOROMETRY FOR THE TYPING OF MALIGNANT AND NON-MALIGNANT LYMPHOID-CELLS
    BERNARD, A
    POIRIER, B
    GELIN, C
    BOUMSELL, L
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1985, 27 (02): : 136 - 136
  • [25] SURFACE-PROPERTIES OF HYBRIDS OF NON-MALIGNANT AND MALIGNANT-CELLS
    FREEDLANSKAYA, II
    POLANSKAYA, GG
    BLOMQUIST, E
    TATULYAN, SA
    PINAEV, GP
    TSITOLOGIYA, 1983, 25 (05): : 593 - 600
  • [26] Neurological manifestations of malignant and non-malignant dysglobulinaemias
    Steck, AJ
    JOURNAL OF NEUROLOGY, 1998, 245 (10) : 634 - 639
  • [27] Radium treatment of malignant and non-malignant diseases
    不详
    BRITISH MEDICAL JOURNAL, 1929, 1929 (02): : 551 - 552
  • [28] LEUCOCYTOTOXICITY IN MALIGNANT AND NON-MALIGNANT COLONIC DISEASES
    VOSE, BM
    MOORE, M
    SCHOFIELD, PF
    DYMOCK, IW
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1975, 22 (03): : 393 - 398
  • [29] The endoscopist and malignant and non-malignant biliary obstruction
    Pereira, S. P.
    Goodchild, G.
    Webster, G. J. M.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (04): : 1478 - 1483
  • [30] Biomarkers and imaging in non-malignant and malignant osteomalacia
    Lüftner, D
    Bollow, M
    Stürzenbecher, A
    Kaufmann, O
    Priem, F
    Richter, A
    Günther, S
    Geppert, R
    Petrides, PE
    Wernecke, KD
    Possinger, K
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (02): : 136 - 141